The U.S. Food and Drug Administration approved Bayer's HYRNUO (sevabertinib) for treating adult patients with locally advanced or metastatic non-squamous ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE